Analysis of 12-month, Phase 3 study shows 2-fold increase in time between VALTOCO treated seizure clusters, or SEIzure interVAL (SEIVAL) SAN DIEGO, Oct. 12, 2022 /PRNewswire/ -- Neurelis, Inc., a ...
SAN DIEGO, Aug. 31, 2023 /PRNewswire/ -- Neurelis, Inc. will present additional clinical findings from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results